2021
DOI: 10.1016/j.lfs.2021.119649
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic potential of AMPK signaling targeting in lung cancer: Advances, challenges and future prospects

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
16
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 45 publications
(18 citation statements)
references
References 246 publications
0
16
0
Order By: Relevance
“…Most NSCLC patients have advanced disease at diagnosis. Platinum-based chemotherapy doublet, including antimicrotubule agents (e.g., paclitaxel/carboplatin and docetaxel/cisplatin), is the standard of care for first-line treatment of advanced NSCLC [3][4][5]. However, only partial responses were achieved with this approach in 30% to 40% of patients [6].…”
Section: Introductionmentioning
confidence: 99%
“…Most NSCLC patients have advanced disease at diagnosis. Platinum-based chemotherapy doublet, including antimicrotubule agents (e.g., paclitaxel/carboplatin and docetaxel/cisplatin), is the standard of care for first-line treatment of advanced NSCLC [3][4][5]. However, only partial responses were achieved with this approach in 30% to 40% of patients [6].…”
Section: Introductionmentioning
confidence: 99%
“…The expression level of Tufm in lung cancer tissues has been shown to be positively correlated with epithelial cell marker protein E-cadherin and negatively correlated with the progression of lung cancer. Knockdown of Tufm inhibited the expression of mitochondrial gene-encoded proteins in lung cancer cells, causing impairment of mitochondrial function and promoting ROS production ( 36 ). The cellular energy and oxidative stress caused by Tufm downregulation can lead to the activation of AMP-activated protein kinase (AMPK).…”
Section: Discussionmentioning
confidence: 99%
“…These parts that do not encode proteins are known as noncoding RNAs and miRNA, lncRNA, and circRNA belong to this group (Pandya et al, 2020). These RNA molecules show regulatory functions in the cells and their aberrant expression has been found in the various tumors (Abadi, Zarrabi et al, 2021; Ashrafizadeh, Ahmadi, Mohammadinejad et al, 2020; Ashrafizadeh, Mirzaei, Hushmandi et al, 2021; Ashrafizadeh, Shahinozzaman et al, 2021; Chen et al, 2019; Z. Ma et al, 2019; Paskeh, Mirzaei, Orouei et al, 2021). Furthermore, circRNAs and lncRNAs regulate miRNA expression via sponging (Chen et al, 2019; Chew et al, 2018; Kirtonia et al, 2021; Mirzaei, Paskeh et al, 2021).…”
Section: Ncrnas In Nf‐κb/emt Regulationmentioning
confidence: 99%